A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study

Abstract

We developed an algorithm that explains 49.99% of the variability in therapeutic VKA dosage in the Chilean population studied. Factors that significantly affected the dosage included <i>VKORC1</i>, <i>CYP2C9*2</i>, and <i>CYP2C9*3</i> polymorphisms, as well as age, sex, BMI, and initial INR.